As of September 30, 2026, Standard BioTools Inc. carries a market capitalization of 292.29M, placing it among publicly traded companies globally. Its enterprise value stands at -141.98M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 292.29M |
| Enterprise Value | -141.98M |
Standard BioTools Inc.'s next confirmed earnings release is scheduled for March 3, 2027.
| Earnings Date | 3/3/2027 |
As of September 30, 2026, Standard BioTools Inc. has 394.67M shares outstanding.
| Shares Outstanding | 394.67M |
As of September 30, 2026, Standard BioTools Inc. trades at a trailing price-to-earnings ratio of 2.17. The price-to-sales ratio is 3.42, and the price-to-book ratio stands at 0.53.
| PE Ratio | 2.17 |
| PS Ratio | 3.42 |
| PB Ratio | 0.53 |
| P/TBV Ratio | 0.53 |
| P/FCF Ratio | -4.39 |
| P/OCF Ratio | -4.49 |
As of September 30, 2026, Standard BioTools Inc. maintains a current ratio of 9.75, meaning it holds 9.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.83, indicating elevated leverage, while an interest coverage ratio of -15,424.20 demonstrates limited ability to service its debt obligations.
| Current Ratio | 9.75 |
| Quick Ratio | 9.29 |
| Debt / Equity | 4.83 |
| Debt / EBITDA | -0.35 |
| Interest Coverage | -15,424.20 |
Over the twelve months ended September 30, 2026, Standard BioTools Inc. posted a return on equity (ROE) of 27.86, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 22.65, measuring how efficiently the asset base is converted into earnings. The company generates approximately 217,043.70 in revenue per employee across its workforce of 389.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.88 indicates how many times Standard BioTools Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 27.86 |
| Return on Assets (ROA) | 22.65 |
| Revenue Per Employee | 217,043.70 |
| Employee Count | 389.00 |
| Inventory Turnover | 1.88 |
Over the twelve months ended September 30, 2026, Standard BioTools Inc. recorded an income tax benefit of -35.80M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -73.03M and 133.08M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.
| Income Tax | -35.80M |
As of the close on November 16, 2026, Standard BioTools Inc.'s stock has declined approximately 49.92% over the past 52 weeks. The 50-day moving average sits at 0.68, while the 200-day moving average is 0.87.
| 52-Week Price Change | -49.92% |
| 50-Day Moving Average | 0.68 |
| 200-Day Moving Average | 0.87 |
Over the twelve months ended September 30, 2026, Standard BioTools Inc. generated 84.43M in revenue and converted that into 133.08M in net income, yielding earnings per share of -0.10. EBITDA reached -77.12M, while operating income came in at -47.26M.
| Revenue | 84.43M |
| Gross Profit | 44.05M |
| Operating Income | -47.26M |
| Pretax Income | -73.03M |
| Net Income | 133.08M |
| EBITDA | -77.12M |
| EBIT | -82.30M |
| Earnings Per Share (EPS) | -0.10 |
As of September 30, 2026, Standard BioTools Inc. holds 461.11M in cash and equivalents against 26.83M in total debt, resulting in a net debt position of -267.19M. Total book value stands at 555.75M, with working capital of 446.28M providing operational flexibility.
| Cash & Cash Equivalents | 461.11M |
| Total Debt | 26.83M |
| Net Debt | -267.19M |
| Equity (Book Value) | 555.75M |
| Book Value Per Share | 1.41 |
| Working Capital | 446.28M |
Standard BioTools Inc. produced -64.26M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -1.39M in capital expenditures, free cash flow totaled -65.65M - equivalent to -0.17 per share.
| Operating Cash Flow | -64.26M |
| Capital Expenditures | -1.39M |
| Free Cash Flow | -65.65M |
| FCF Per Share | -0.17 |
Over the twelve months ended September 30, 2026, Standard BioTools Inc. posted a gross margin of 52.18, reflecting its pricing power and cost economics. The operating margin of -55.98 and net profit margin of 157.62 provide insight into operational efficiency.
| Gross Margin | 52.18 |
| Operating Margin | -55.98 |
| Pretax Margin | -86.50 |
| Profit Margin | 157.62 |
| EBITDA Margin | -91.34 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -22.76: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.05, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Standard BioTools Inc. shareholders.
| Shareholder Yield | 0.05 |
| FCF Yield | -22.76 |
As of September 30, 2026, Standard BioTools Inc. has an Altman Z-Score of 0.41, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 0.41 |